Generic placeholder image

Anti-Cancer Agents in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1871-5206
ISSN (Online): 1875-5992

Biography

Meet the Editorial Board Member

Author(s): Alessandro Desideri

Volume 23, Issue 4, 2023

Published on: 21 December, 2022

Page: [367 - 367] Pages: 1

DOI: 10.2174/187152062304221221120623

conference banner
Next »
[1]
Unida, V.; Vindigni, G.; Raniolo, S.; Stolfi, C.; Desideri, A.; Biocca, S. Folate-functionalization enhances cytotoxicity of multivalent DNA nanocages on triple-negative breast cancer cells. Pharmaceutics, 2022, 14(12), 2610.
[2]
Ottaviani, A.; Iacovelli, F.; Welsch, J.; della Rocca, M.B.; Desideri, A. Dimethylmyricacene: An in vitro and in silico study of a semisynthetic non-camptothecin derivative compound, targeting human DNA topoisomerase 1B. Cells, 2022, 11(21), 3486.
[3]
Vindigni, G.; Raniolo, S.; Iacovelli, F.; Unida, V.; Stolfi, C.; Desideri, A.; Biocca, S. AS1411 aptamer linked to DNA nanostructures diverts its traffic inside cancer cells and improves its therapeutic efficacy. Pharmaceutics, 2021, 13(10), 1671.
[4]
Ottaviani, A.; Iacovelli, F.; Fiorani, P.; Desideri, A. Natural compounds as therapeutic agents: The case of human topoisomerase ib. Int. J. Mol. Sci., 2021, 22(8), 4138.
[5]
Raniolo, S.; Unida, V.; Vindigni, G.; Stolfi, C.; Iacovelli, F.; Desideri, A.; Biocca, S. Combined and selective miR-21 silencing and doxorubicin delivery in cancer cells using tailored DNA nanostructures. Cell Death Dis., 2021, 12(1), 1-9.

© 2024 Bentham Science Publishers | Privacy Policy